Evaluation of safety and efficacy of autologous adipose-derived mesenchymal cells therapy in Duchenne muscular dystrophy patients

Research Deputy of Islamic Azad University, Tehran Medical Branch0 个研究点目标入组 10 人开始时间: 待定最近更新: 2022年6月27日

试验速览

暂无简介。

•Genetic evidence of Duchenne disease as a cause of myopathy
•The patient's ability to walk is not completely lost and the use of assistive devices such as canes and walkers is not permanent.
•The patient's muscle strength is decreasing
•Willingness and satisfaction to participate in the study by the patient's legal guardian in decision making and willingness to participate regularly in follow-up courses

•Advanced motor impairment leading to permanent use of crutches, walkers and wheelchairs
•A history of known malignancy
•History of associated genetic and non-genetic degenerative diseases
•Having blood and internal diseases that increase the risk of liposuction and anesthesia required
•A history of any other acute or chronic illness that, at the discretion of the clinician responsible for implementing the plan, prevents the patient from entering the study.
•Insufficient volume of subcutaneous fat or the presence of concomitant injuries in the abdomen in the initial examination that make it difficult to obtain adipose tissue to prepare SVF.

发起方

Research Deputy of Islamic Azad University, Tehran Medical Branch